Circassia Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Circassia Pharmaceuticals plc
Public limited company
Traded as LSECIR
Industry Pharmaceuticals
Founded 2006
Headquarters Oxford, United Kingdom
Key people
Francesco Granata, (Chairman)
Steven Harris, (CEO)
Revenue £10.8 million (2015)[1]
£(66.4) million (2015)[1]
£(50.0) million (2015)[1]

Circassia Pharmaceuticals is a specialty biopharmaceutical company developing a range of immunotherapies. It is listed on the London Stock Exchange.


The company was founded by Steve Harris and Charles Swingland in 2006.[2] It was the subject of an Initial Public Offering in March 2014.[3]


The company's technology, ToleroMune, was initially developed by scientists at Imperial College London.[2] The company is in the process of developing a treatment for cat allergies.[4]


  1. ^ a b c "Accounts for year ended 31 December 2015". Circassia Pharmaceuticals. Retrieved 31 March 2016. 
  2. ^ a b "Fundamentals for Circassia Pharmaceuticals Ord 0.08p". The Telegraph. Retrieved 23 August 2014. 
  3. ^ "Circassia IPO Fuels Optimism on European Biotech". Wall street Journal. 13 March 2014. Retrieved 23 August 2014. 
  4. ^ "Hope of cat allergy cure brings Circassia to stock market". The Telegraph. 6 February 2014. Retrieved 23 August 2014. 

External links[edit]